FNAM
Evolutionary Genomics, Inc. [FNAM] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
FNAM Stock Summary
In the News
FNAM Financial details
Company Rating
Neutral
Market Cap
2.99M
Income
-254.77K
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
2
Optionable
No
Shortable
Yes
Earnings
09 Mar 2024
P/E
-3.31
Forward P/E
-
PEG
0.36
P/S
-
P/B
-0.47
P/C
-
P/FCF
-9.34
Quick Ratio
3.68
Current Ratio
3.92
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.04
EPS next Y
-
EPS next Q
-
EPS this Y
-36.96%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
8.83%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-34%
ROE
15%
ROC
-0.44%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.45-0.72
52W High
-
52W Low
-
RSI
-
Rel Volume
0.72
Avg Volume
416
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
-0.357
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-
FNAM Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.02 | 0.02 | 0 | 0 | 0 | |
| Net income per share | -0.19 | -0.13 | -0.29 | -0.46 | -0.29 | |
| Operating cash flow per share | -0.13 | -0.11 | -0.39 | -0.27 | -0.1 | |
| Free cash flow per share | -0.13 | -0.11 | -0.39 | -0.27 | -0.1 | |
| Cash per share | 0.03 | 0.01 | 0.04 | 0.04 | 0.09 | |
| Book value per share | 0.07 | -0.06 | -0.31 | -0.75 | -0.87 | |
| Tangible book value per share | -0.62 | -0.74 | -0.93 | -1.2 | -1.12 | |
| Share holders equity per share | 0.07 | -0.06 | -0.31 | -0.75 | -0.87 | |
| Interest debt per share | 0 | 0 | 0.38 | 0.64 | 0.57 | |
| Market cap | 1.47M | 8.82M | 6.47M | 4.12M | 4.52M | |
| Enterprise value | 1.34M | 8.78M | 8.5M | 7.65M | 7.69M | |
| P/E ratio | -1.34 | -11.12 | -3.78 | -1.52 | -2.44 | |
| Price to sales ratio | 12.81 | 71.91 | 517.61 | 0 | 0 | |
| POCF ratio | -1.96 | -14.09 | -2.82 | -2.6 | -7.05 | |
| PFCF ratio | -1.96 | -14.09 | -2.82 | -2.6 | -7.05 | |
| P/B Ratio | 3.64 | -26.44 | -3.54 | -0.94 | -0.81 | |
| PTB ratio | 3.64 | -26.44 | -3.54 | -0.94 | -0.81 | |
| EV to sales | 11.66 | 71.54 | 680.01 | 0 | 0 | |
| Enterprise value over EBITDA | -2.51 | -11.74 | -3.21 | -3.98 | -7.73 | |
| EV to operating cash flow | -1.79 | -14.02 | -3.7 | -4.83 | -11.99 | |
| EV to free cash flow | -1.79 | -14.02 | -3.7 | -4.83 | -11.99 | |
| Earnings yield | -0.75 | -0.09 | -0.26 | -0.66 | -0.41 | |
| Free cash flow yield | -0.51 | -0.07 | -0.36 | -0.38 | -0.14 | |
| Debt to equity | 0 | 0 | -1.23 | -0.85 | -0.67 | |
| Debt to assets | 0 | 0 | 0.56 | 1.28 | 1.59 | |
| Net debt to EBITDA | 0.25 | 0.06 | -0.77 | -1.84 | -3.19 | |
| Current ratio | 0 | 6.09 | 87.73 | 13.56 | 3.92 | |
| Interest coverage | 0 | 0 | 0 | 0 | 25.39 | |
| Income quality | 0.68 | 0.79 | 1.34 | 0.57 | 0.33 | |
| Dividend Yield | 0.16 | 0.03 | 0.04 | 0 | 0 | |
| Payout ratio | -0.22 | -0.34 | -0.16 | 0 | 0 | |
| Sales general and administrative to revenue | 4.16 | 3.46 | 87.93 | 0 | 0 | |
| Research and developement to revenue | 4.13 | 3.85 | 143.45 | 0 | 0 | |
| Intangibles to total assets | 0.92 | 0.95 | 0.92 | 0.91 | 0.7 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0.86 | 0.46 | 17.58 | 0 | 0 | |
| Graham number | 0.54 | 0.41 | 1.43 | 2.78 | 2.36 | |
| ROIC | -1.58 | 2.42 | -4.35 | 4.25 | 1.04 | |
| Return on tangible assets | -3.14 | -3.83 | -5.21 | -9.87 | -2.64 | |
| Graham Net | -0.65 | -0.77 | -0.95 | -1.21 | -1.13 | |
| Working capital | 223.42K | 98.75K | 274.43K | 236.94K | 520.67K | |
| Tangible asset value | -3.63M | -4.37M | -5.49M | -7.06M | -7.24M | |
| Net current asset value | -3.76M | -4.46M | -5.54M | -7.08M | -7.25M | |
| Invested capital | 0 | 0 | -1.23 | -0.85 | -0.67 | |
| Average receivables | 20.22K | 23.64K | 3.42K | 0 | 39K | |
| Average payables | 0 | 9.71K | 11.29K | 11.02K | 98.55K | |
| Average inventory | 0 | -20.85K | -20.85K | 0 | 0 | |
| Days sales outstanding | 128.56 | 20.36 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 34.43 | 0 | 6.63 | 63.69 | |
| Days of inventory on hand | 0 | -73.94 | 0 | 0 | 0 | |
| Receivables turnover | 2.84 | 17.92 | 0 | 0 | 0 | |
| Payables turnover | 0 | 10.6 | 0 | 55.06 | 5.73 | |
| Inventory turnover | 0 | -4.94 | 0 | 0 | 0 | |
| ROE | -2.72 | 2.38 | 0.94 | 0.62 | 0.33 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.08 | -0.04 | 0 | 0 | 0 | |
| Operating cash flow per share | -0.02 | -0.03 | 0 | 0 | 0 | |
| Free cash flow per share | -0.02 | -0.03 | 0 | 0 | 0 | |
| Cash per share | 0.12 | 0.09 | 0 | 0 | 0 | |
| Book value per share | -0.79 | -0.84 | 0 | 0 | 0 | |
| Tangible book value per share | -1.07 | -1.09 | 0 | 0 | 0 | |
| Share holders equity per share | -0.79 | -0.84 | 0 | 0 | 0 | |
| Interest debt per share | 0.56 | 0.55 | 0 | 0 | 0 | |
| Market cap | 4.66M | 4.66M | 0 | 0 | 0 | |
| Enterprise value | 7.64M | 7.83M | 0 | 0 | 0 | |
| P/E ratio | -2.14 | -4.57 | 0 | 0 | 0 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -35.23 | -24.72 | 0 | 0 | 0 | |
| PFCF ratio | -35.23 | -24.72 | 0 | 0 | 0 | |
| P/B Ratio | -0.89 | -0.83 | 0 | 0 | 0 | |
| PTB ratio | -0.89 | -0.83 | 0 | 0 | 0 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -26.27 | -49.73 | 0 | 0 | 0 | |
| EV to operating cash flow | -57.75 | -41.52 | 0 | 0 | 0 | |
| EV to free cash flow | -57.75 | -41.52 | 0 | 0 | 0 | |
| Earnings yield | -0.12 | -0.05 | 0 | 0 | 0 | |
| Free cash flow yield | -0.03 | -0.04 | 0 | 0 | 0 | |
| Debt to equity | -0.71 | -0.67 | 0 | 0 | 0 | |
| Debt to assets | 1.39 | 1.59 | 0 | 0 | 0 | |
| Net debt to EBITDA | -10.24 | -20.12 | 0 | 0 | 0 | |
| Current ratio | 4.9 | 3.92 | 0 | 0 | 0 | |
| Interest coverage | 1.35K | 5.25 | 0 | 0 | 0 | |
| Income quality | 0.24 | 0.56 | 0 | 0 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.71 | 0.7 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.2 | 0.85 | 0 | 0 | 0 | |
| ROIC | 0.36 | 0.17 | 0 | 0 | 0 | |
| Return on tangible assets | -0.69 | -0.36 | 0 | 0 | 0 | |
| Graham Net | -1.08 | -1.1 | 0 | 0 | 0 | |
| Working capital | 618.68K | 520.67K | 0 | 0 | 0 | |
| Tangible asset value | -7.14M | -7.24M | 0 | 0 | 0 | |
| Net current asset value | -7.15M | -7.25M | 0 | 0 | 0 | |
| Invested capital | -0.71 | -0.67 | 0 | 0 | 0 | |
| Average receivables | 0 | 39K | 39K | 0 | 0 | |
| Average payables | 126.19K | 168.38K | 89.12K | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 123.33 | 62.82 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.73 | 1.43 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.1 | 0.05 | 0 | 0 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
FNAM Frequently Asked Questions
What is Evolutionary Genomics, Inc. stock symbol ?
Evolutionary Genomics, Inc. is a US stock , located in Castle rock of Co and trading under the symbol FNAM
What is Evolutionary Genomics, Inc. stock quote today ?
Evolutionary Genomics, Inc. stock price is $- today.
Is Evolutionary Genomics, Inc. stock public?
Yes, Evolutionary Genomics, Inc. is a publicly traded company.
Company Profile
- Volume Average 416
- Market Capitalization 2.99M
- Employee 2
- CEO Mr. Steve B. Warnecke
- Headquarters Castle Rock,CO,US
- IPO Date 2012-05-15
-
Website
https://www.evolgen.com 
Evolutionary Genomics, Inc., together with its subsidiaries, engages in the research and identification of positively selected genes in humans, animals, and commercial crops. The company develops Adapted Traits Platform, a technology platform to identify genes for enhancing crop plant traits, such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. It serves governmental organizations, non-profit foundations, and commercial entities. Evolutionary Genomics, Inc. was incorporated in 1990 and is based in Castle Rock, Colorado.
